01—Abstract
Summary
Summary of the 8-K filed February 11, 2025. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences (GILD) reported fourth quarter and full year 2024 results on February 11, 2025, showing strong commercial momentum in its base business alongside large non-cash charges that depressed GAAP earnings.
Full-year 2024 total revenue rose 6% to $28.8 billiona, with product sales excluding Veklury up 8% to $26.8 billion, led by HIV (Biktarvy sales up 13% to $13.4 billion). Fourth-quarter revenue grew 6% to $7.6 billion and GAAP diluted EPS rose to $1.42 from $1.14, while full-year GAAP diluted EPS fell sharply to $0.38 from $4.50 due to a $4.2 billion IPR&D impairment tied to Immunomedics assets and $3.9 billion of acquired IPR&D charges from the CymaBay acquisition. Non-GAAP full-year diluted EPS declined to $4.62 from $6.72, reflecting the CymaBay charge and higher taxes.
Management's 2025 guidance projects product sales of $28.2 to $28.6 billionb, with non-GAAP diluted EPS of $7.70 to $8.10, and the company is preparing for a potential summer 2025 launch of twice-yearly lenacapavir for HIV PrEP, for which regulatory submissions have been completed. Balance sheet and cash generation remained solid, with full-year operating cash flow of $10.8 billion, free cash flow of $10.3 billion, and cash and marketable securities of $10.0 billion at year end, though the company issued $3.5 billion in senior notes during the quarter and declared a $0.79 quarterly dividend for Q1 2025. Investors should weigh the strong underlying franchise and growth outlook against risks including Veklury's declining contribution, Biktarvy and HIV dependence, pricing and payer pressure, and the company's continued reliance on acquisitions and in-process R&D, which drive periodic GAAP earnings volatility.
02—Key points
Key Highlights
- FY2024 total revenue rose 6% to $28.8 billion; product sales excluding Veklury grew 8% to $26.8 billion, with Biktarvy up 13% to $13.4 billion.
- Q4 2024 GAAP diluted EPS was $1.42 (vs. $1.14) and non-GAAP diluted EPS was $1.90 (vs. $1.72), with Q4 product gross margin of 79.0% GAAP and 86.7% non-GAAP.
- FY2024 GAAP diluted EPS fell to $0.38 from $4.50, driven by a $4.2 billion Immunomedics-related IPR&D impairment and $3.9 billion of CymaBay-related acquired IPR&D charges; non-GAAP diluted EPS declined to $4.62 from $6.72.
- 2025 guidance: product sales of $28.2–$28.6 billion, non-GAAP diluted EPS of $7.70–$8.10, and GAAP diluted EPS of $5.95–$6.35, with Veklury expected at about $1.4 billion.
- Lenacapavir for HIV PrEP is in regulatory review (NDA submitted to FDA), with a potential U.S. launch planned for summer 2025, a key growth catalyst.
- Strong cash generation: FY2024 operating cash flow of $10.8 billion and free cash flow of $10.3 billion, ending the year with $10.0 billion in cash and marketable debt securities.
- Capital returns and financing: $973 million in Q4 dividends, $350 million of Q4 share repurchases, $3.5 billion senior notes issuance, and a $0.79 quarterly dividend declared for Q1 2025.
03—Questions
Frequently Asked Questions
Why did Gilead's GAAP EPS fall so sharply in 2024 despite revenue growth?
Full-year 2024 GAAP diluted EPS fell to $0.38 from $4.50 mainly because of non-cash and one-time charges: a $4.2 billion (about $2.49 per share after tax) IPR&D impairment on assets acquired from Immunomedics in 2020, and $3.9 billion of acquired IPR&D charges (about $3.14 per share) from the CymaBay acquisition. Higher tax expense from the non-deductible CymaBay charge also weighed on results. Underlying product sales growth partially offset these items.
How much of Gilead's business depends on HIV, and what is the outlook?
HIV is the core franchise, generating $19.6 billion of 2024 product sales, or roughly 69% of total product sales, with Biktarvy alone at $13.4 billion. Management expects continued HIV demand growth and is preparing a potential 2025 launch of lenacapavir for PrEP. The concentration is a risk, since competition, pricing, payer mix shifts and eventual loss of exclusivity could affect results.
What does the 2025 guidance imply for investors?
Gilead guided to 2025 product sales of $28.2–$28.6 billion (including Veklury at about $1.4 billion) and non-GAAP diluted EPS of $7.70–$8.10, implying modest top-line growth versus 2024 and substantial non-GAAP earnings growth from the 2024 base, which was depressed by CymaBay-related charges. GAAP guidance is lower at $5.95–$6.35 per diluted share because of expected acquisition-related amortization and restructuring expenses. Guidance excludes unexecuted acquisitions and future fair value adjustments.
Is Gilead's dividend and balance sheet at risk given the recent debt issuance?
Gilead remains well-funded. It ended 2024 with $10.0 billion in cash and marketable securities and generated $10.3 billion of free cash flow in 2024, which comfortably covers its dividend (about $3.08 per share declared in 2024, with $0.79 declared for Q1 2025). The $3.5 billion senior notes issuance was used to refinance and manage its capital structure, while total stockholders' equity fell to $19.2 billion from $22.7 billion largely because of the 2024 impairment and acquired IPR&D charges. Total debt-related obligations remain a consideration given long-term liabilities of $27.7 billion.
What is driving the Q4 2024 gross margin improvement?
Product gross margin rose to 79.0% in Q4 2024 from 70.4% in Q4 2023, largely because the prior year included restructuring expenses tied to changes in manufacturing strategy. On a non-GAAP basis, product gross margin was 86.7% versus 86.1%, a more modest improvement that reflects underlying operating performance. Gross margin on a GAAP basis remains affected by acquisition-related amortization of intangibles, which was about 7.7 percentage points in Q4 2024.
04—Continue